$BSEM So with no update really on uplifting and the Acquisition of Bio Tissue Holding completed, I’m guessing we need to wait till August for both Improved Earnings as well as Uplifting of stock to Nasdaq!!!
$BSEM The snake oil selling executive team keeps trying to convince people the future is great. Well it’s unlikely. I don’t see how they can get on the Nasdaq after misrepresenting their financial statements over the last couple of yrs. Have the executives compensation been clawed back for that misrepresentation?
$BSEM Q1 '26 Earnings Results & Recap
BioStem Technologies expects full year 2026 revenue to range from $25M to $29M, with sequential growth in both hospital and physician office businesses anticipated in the second half of 2026.
(OTC: $BSEM) BioStem Technologies
Watching this in 2026 for the $25 target and uplisting potential
✅7 straight profitable quarters
✅$25.50 Zacks target
✅Nasdaq uplisting in focus
BSEM kicked off 2026 with a major acquisition valued at up to $40M, adding Neox® and Clarix® while expanding into hospital based wound care.
With 88.5% gross margins, $10.5M quarterly revenue, and expected added annual revenue from the deal, this is a profitable small cap worth watching.
Communicated Disclaimer
https://www.ztradez.net/communicated-disclaimer
$BYND $OPEN
$BSEM
Per Barchart:
Support & Resistance
3rd Resistance Point 7.4765
2nd Resistance Point 6.7833
1st Resistance Point 6.2366
Last Price 5.6900
1st Support Level 4.9967
2nd Support Level 4.3035
3rd Support Level 3.7568
$BSEM Alright ! Back up over $5 ! We should continue on up over $6. With the forward guidance given with earnings we know we are headed up. The uplifting should be announced fairly soon!
PRISM Mid-Day Movers: Pharmaceuticals and Global Health are Today’s Leaders.
Biodexa Pharmaceuticals (Nasdaq: $BDRX) is surging to about $1.05, up roughly 70% on heavy volume, yet still down over 90% in the past year as it heads into an April 6, 2026 1‑for‑5 ADR reverse split and remains a speculative, catalyst‑driven oncology play in tough‑to‑treat cancers.
Lexaria Bioscience (Nasdaq: $LEXX) is trading just under $1.00, up about 17% as investors eye upcoming GLP‑1 catalysts following positive Human Pilot Study #5 data showing its oral DehydraTECH‑liraglutide performed comparably to injected Saxenda and kicking off a 2026 R&D program with new human and multi‑arm animal GLP‑1 studies.
Other Notable Movers:
BioStem Technologies ( $BSEM) up 16%
Korro Bio ( $KRRO) up 10%
Lipocine Inc ( $LPCN) down -78%
https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-global-health-are-todays-leaders/
$BSEM Good to see the audit complete. What they show is the original 2024 results were announced, and many investors bought based on those results, have now been reinstated from $301.8m to $69.7m because of incorrect accounting practices. Similar declines occured in 2025 in the 1st half before redefining their accounting procedures. Those results were based on end user selling prices most likely at $2K per sq cm which is now being reduced to $127 in 2026. Those fooled by the inflated and incorrect accounting practices most likely have a legal justification for recover of their losses, but that’s up to you and your lawyer.
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Valuation
Trading at 0.2× sales vs its 2.9× historical median P/S.
Fair value ≈ $45.59 · price $3.35 today
Undervalued · 93% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
